<DOC>
	<DOCNO>NCT02660580</DOCNO>
	<brief_summary>The purpose study compare efficacy , safety immunogenicity MSB11022 HumiraÂ® adult subject moderate severe chronic plaque type psoriasis .</brief_summary>
	<brief_title>MSB11022 Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male female subject great equal ( &gt; = ) 18 year old clinical diagnosis stable moderate severe plaque psoriasis ( defined Psoriasis Area Severity Index [ PASI ] score &gt; =12 , Physician Global Assessment [ PGA ] score &gt; =3 , &gt; =10 % body surface area affect Screening Baseline [ Day 1 Week 1 ] ) history receipt candidate systemic therapy phototherapy active plaquetype psoriasis despite topical therapy Subjects must receive 1 biologic therapy Other protocoldefined inclusion criterion could apply Subjects excluded erythrodermic , pustular , guttate , medicationinduced form psoriasis active skin diseases/infections may interfere evaluation plaque psoriasis Subjects must receive adalimumab investigational license biosimilar adalimumab ; topical therapy treatment psoriasis ultraviolet B phototherapy within 2 week investigational medicinal product ( IMP ) administration plan take treatment trial ; psoralen combine ultraviolet A phototherapy nonbiological systemic therapy psoriasis within 4 week prior IMP administration Subjects also exclude history ongoing , chronic , recurrent infectious disease ( except latent tuberculosis [ TB ] ) ; history active TB ; history hypersensitivity component IMP formulation , comparable drug , latex Other protocoldefined exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adalimumab</keyword>
	<keyword>MSB11022</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Phase III</keyword>
</DOC>